Syros Pharmaceuticals Inc

NASDAQ: SYRS
$5.01
+$0.01 (+0.2%)
Closing price May 9, 2024

SYRS Chart and Intraday Price

SYRS Company Data

Asset Type Stock
Exchange NASDAQ
Currency USD
Country USA
Sector LIFE SCIENCES
Industry PHARMACEUTICAL PREPARATIONS
Address 620 MEMORIAL DRIVE, SUITE 300, CAMBRIDGE, MA, US
Fiscal Year End December
Latest Quarter 9/30/2023
Market Cap 201.55M USD
Shares Outstanding 26,006,700
Syros Pharmaceuticals Inc is a pioneering biopharmaceutical firm based in Cambridge, Massachusetts, dedicated to developing innovative treatments for blood cancers. Its leading products include Tamibarotene, aimed at certain myelodysplastic syndrome patients and acute myeloid leukemia, SY-2101 for acute promyelocytic leukemia, and SY-5609 for advanced solid tumors. The company, established in 2011, collaborates with Incyte Corporation and TMRC Co. Ltd. to advance its research and bring new therapies to market.

SYRS Articles

Here's What Insiders Are Buying to Wrap Up the Year
As the year wound to a close, the most notable insider buying was focused on biotech stocks, but an oil and gas company CEO also returned to the buy window.
Trey Thoelcke
Published: